rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2007-3-26
|
pubmed:abstractText |
Drug-induced QT interval prolongation has been one of the critical issues for developing new chemical entities and pharmaceutical companies need to evaluate the risk early in the development stage. At such stage, guinea pigs are appropriate due to their small size requiring only small amounts of test drugs. The purpose of this study was to determine the utility of guinea pig monophasic action potential (MAP) using 12 reference drugs in order to clarify prediction of the QT interval prolonging risk.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1056-8719
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
254-61
|
pubmed:meshHeading |
pubmed-meshheading:17229580-Action Potentials,
pubmed-meshheading:17229580-Animals,
pubmed-meshheading:17229580-Biological Markers,
pubmed-meshheading:17229580-Drug Evaluation, Preclinical,
pubmed-meshheading:17229580-Electrocardiography,
pubmed-meshheading:17229580-Guinea Pigs,
pubmed-meshheading:17229580-Long QT Syndrome,
pubmed-meshheading:17229580-Male,
pubmed-meshheading:17229580-Models, Animal,
pubmed-meshheading:17229580-Pharmaceutical Preparations,
pubmed-meshheading:17229580-Predictive Value of Tests,
pubmed-meshheading:17229580-Risk Assessment,
pubmed-meshheading:17229580-Sensitivity and Specificity,
pubmed-meshheading:17229580-Torsades de Pointes,
pubmed-meshheading:17229580-Ventricular Function
|
pubmed:articleTitle |
Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
|
pubmed:affiliation |
Safety Assessment Department, Chugai Pharmaceutical Co., Ltd., Shizuoka 412-8513, Japan. tabomty@chugai-pharm.co.jp
|
pubmed:publicationType |
Journal Article
|